KURA Stock Pops After Promising Early Cancer Data — What Investors Should Know

• The treatment showed an objective response rate of 44% and a disease control rate of 94%.
• Kura said tumor shrinkage was seen in 75% of the 16 patients on trial.
• The results were presented at the International Kidney Cancer Symposium Europe 2026 in Paris.

Shares of Kura Oncology (KURA) jumped more than 13% in pre-market trading on Friday after the clinical-stage biotech firm reported encouraging early data from its ongoing trial for the treatment of advanced kidney cancer.

The results, presented at the International Kidney Cancer Symposium Europe 2026 in Paris, focused on patients with clear cell renal cell carcinoma (ccRCC).

If the pre-market levels hold after the opening bell, KURA shares would hit their highest levels since Jan. 7, 2026.

Strong Response Rates, But Small Sample Size

Kura shared initial results from an ongoing FIT-001 trial testing its investigational therapy, Darlifarnib, in combination with Cabozantinib, a type of target enzyme inhibitor, in kidney cancer patients who had already been treated with Cabozantinib.

The treatment showed an objective response rate of 44% and a disease control rate of 94%. Tumor shrinkage was seen in 75% of patients, including those who had previously shown limited response to Cabozantinib.

Of the 16 patients receiving treatment over an 8- to 56-week period, six are still receiving therapy at the time of the analysis, the company said.

What Investors Should Watch Next

The treatment also demonstrated a manageable safety profile across different dose levels. The study is testing Darlifarnib at daily doses of 3 mg, 5 mg, or 8 mg, taken in cycles of 7 days on and 7 days off, along with daily Cabozantinib at 60 mg or 40 mg. All patients in the study have previously received immunotherapy.

The study is now advancing into Phase 1b to further evaluate the optimal dosing and potential benefits of the regimen.

How Did Retail Traders React?

Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish,’ amid ‘extremely high’ message volumes.

One user expects the run-up to start soon.

Another user expects “positive news” from the company’s conference call.

Year-to-date, the stock has shed around 15%.

For updates and corrections, email newsroom[at]stocktwits[dot]com.